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Alzheimer’s disease (AD) is perhaps the
principal example of cognitive failure in
humans, and currently over 5.5 million
Americans suffer from this incapacitat-
ing and progressive disorder of thought,
reasoning and memory. Our laboratory
has been evaluating the potential con-
tribution of environmentally bioavailable
neurotoxic metals to the onset, develop-
ment and progression of AD for about 30
years (Lukiw et al., 1987). Largely because
of its known multiple and potent neu-
rotoxic effects, much of our research has
focused on the potential contribution of
aluminum to the AD process: (i) because
of aluminum’s remarkable abundance and
bioavailability in the biosphere—in fact
it is the most abundant naturally occur-
ring neurotoxic element to which we
are exposed; (ii) because of aluminum’s
remarkable cellular toxicity and genotox-
icity at low nanomolar concentrations
toward brain genetic processes, and (iii)
because of aluminum’s highly structured,
specific and unique interactions with the
phosphate-rich nucleic acids associated
with the expression of genetic information
in the human brain (Lukiw et al., 1989;
Bryant et al., 2004; Alexandrov et al., 2005,
2013; Lukiw and Pogue, 2007; Pogue et al.,
2009, 2012; Lukiw, 2010; Percy et al., 2011;
Bhattacharjee et al., 2013; De Sole et al.,
2013).
Aluminum’s contribution to AD is
based upon at least seven indepen-
dently derived observations: (i) that at
physiologically realistic concentrations,
aluminum strongly promotes amyloid
aggregation and accumulation, a key
feature of AD neuropathology (Exley,
2005; Rodella et al., 2008; Walton and
Wang, 2009; Yumoto et al., 2009); (ii)
that both in vitro and in vivo aluminum
promotes inflammatory signaling via the
pro-inflammatory transcription factor
NF-kB, another prominent feature charac-
teristic of AD brain (Bondy, 2013; Walton,
2013); (iii) that out of the many thousands
of brain gene messenger RNA (mRNAs)
and micro RNAs (miRNAs), the fam-
ily of mRNAs and miRNAs induced by
aluminum are also strikingly similar to
those found to be increased in AD; (iv)
that in transgenic animal models of AD
dietary aluminum enhances the devel-
opment of pathological markers such
as lipid peroxidation, oxidative stress,
apoptosis, and gene expression deficits
(Praticò et al., 2002; Bharathi et al., 2008;
Zhang et al., 2012); (v) that many of the
observed deficits in AD such as chromatin
compaction, impaired energy utilization,
impaired signaling involving chemical
messengers such as adenine triphosphate
(ATP) are recapitulated in aluminum-
treated cellular or animal models of AD
(Alexandrov et al., 2005; Lukiw and Pogue,
2007; Pogue et al., 2012; Bhattacharjee
et al., 2013); (vi) that a very significant
number of studies link the amount of alu-
minum in drinking water to the incidence
of AD [worldwide, aluminum is added
to drinking water as hydrated aluminum
potassium sulfate KAl(SO4)2·12H2O, or
alum, as a clarification and “finishing”
agent (Flaten, 2001; Frisardi et al., 2010;
Walton, 2013)], and (vii) perhaps most
importantly, that of all pharmaceutical
treatment approaches directed against AD
to date, chelation using the anti-oxidant
and trivalent iron/aluminum chelator des-
ferrioxamine has been shown to be one of
themost effective therapeutic strategies yet
devised (Crapper McLachlan et al., 1991;
Percy et al., 2011).
Abundant research indicates that alu-
minum is a particularly reactive metal
toward multiple aspects of human neu-
robiology and the altered genetics that
are associated with the development and
propagation of sporadic AD (Lukiw et al.,
1989; Lukiw, 2010; Bhattacharjee et al.,
2013; Bondy, 2013; Shaw and Tomljenovic,
2013; Walton, 2013). Thirty years of
research since the potent effects of alu-
minum on the genetic apparatus in AD
were first described, the most recent evi-
dence suggests a strong linkage between
aluminum sulfates and induction of NF-
kB-sensitive pro-inflammatory miRNAs
(Lukiw et al., 1987; Alexandrov et al.,
2013; Zhao et al., 2013). Aluminum has
been previously shown to significantly
induce the transcription factor NF-kB
(Pogue et al., 2009; Bondy, 2013), and
up-regulation of NF-kB drives synthesis
of NF-kB-sensitive miRNAs which in turn
down regulate the expression of many
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FIGURE 1 | Array-based cluster analysis of miRNA abundance in aluminum-fed Tg2576 mice
vs. controls. In these experiments the brain (cortex) of 3 month-old Tg2576 mice fed
aluminum-enriched diets were analyzed for miRNA speciation compared to age-matched controls
(receiving standard diets); methodologies for aluminum-treatment of transgenic animals have been
previously described in detail (Praticò et al., 2002; Zhang et al., 2012). Aluminum treatment of other
transgenic murine AD models such as the amyloid over-expressing APP/PS1 show similar
intensification of AD-type changes (Zhang et al., 2012). The up-regulation of the pro-inflammatory
quintet of miRNA-9, miRNA-34a, miRNA-125b, miRNA-146a, and miRNA-155, depicted here, were
amongst the most significantly increased miRNAs found to be 2- to 5-fold above normal diet,
age-matched controls (compared to an unchanging internal control miRNA-183 and 5SRNA in the
same samples). The results strongly suggest a potential contribution of aluminum to the AD
processes associated with miRNA-mediated down-regulation of gene expression in the sporadic
AD brain as is widely observed (Colangelo et al., 2002; Lukiw and Pogue, 2007; Ginsberg et al.,
2012; Pogue et al., 2012; Alexandrov et al., 2013). Importantly, other common environmental
neurotoxic divalent metals such as calcium, cadmium, copper, iron (2+), mercury, nickel, and lead,
and neurotoxic trivalent metals such as boron, chromium, gadolinium, indium, iron (3+), and yttrium
do not exhibit this potentially pathogenic effect (Walker et al., 1989; Alexandrov et al., 2005; Lukiw,
2010; unpublished observations); N = 3 control and N = 3 aluminum-treated mice; methodologies
and data analysis have been extensively described elsewhere (Lukiw and Pogue, 2007; Alexandrov
et al., 2013).
AD-relevant genes, including complement
factor H (CFH) and neurotropic signaling
in human brain cells (Pogue et al., 2009;
Zhao et al., 2013).
We would like here to briefly include
some recent genetic data on aluminum
and its effects on miRNA abundance
in a highly relevant transgenic animal
model for AD that shows strong paral-
lels to miRNA profiles which are found
in AD brain (Figure 1). There are cur-
rently over 90 transgenic mouse models of
AD (http://www.alzforum.org/research-
models/). A commonly used Tg2576
mousemodel overexpresses a mutant form
of beta amyloid precursor protein (β
APP), APPK670/671L, linked to early-
onset familial AD, and develops amy-
loid plaques and progressive cognitive
deficits as the mice age. Tg2576 mice
exposed to dietary aluminum have been
shown to develop oxidative stress and
robust amyloidogenesis, key features of
AD neuropathology (Praticò et al., 2002).
Animals provided a 2mg/kg aluminum-
supplemented diet were analyzed for
miRNA speciation and complexity in
their brains using GeneChip and miRNA
array technologies; intriguingly, the same
quintet of up-regulated pro-inflammatory
miRNAs (miRNA-9, miRNA-34a, miRNA-
125b, miRNA-146a, and miRNA-155) as
found in (i) AD and (ii) in aluminum-
treated human brain cells in primary cul-
ture were also found to be amongst the
most up-regulated in these aluminum-
supplemented Tg2576 mice (Alexandrov
et al., 2005; Lukiw and Pogue, 2007;
Pogue et al., 2012; Bhattacharjee et al.,
2013; Hill et al., 2014; Figure 1; unpub-
lished observations). Up-regulated miR-
NAs are known to target susceptible
mRNAs and down-regulate the expres-
sion of many AD-relevant brain genes
as is widely observed in AD brain tis-
sues (Colangelo et al., 2002; Guo et al.,
2010; Ginsberg et al., 2012). Interestingly,
these findings suggest some common
miRNA-induced mechanism between two
important in vitro and in vivo models for
AD with AD itself. Indeed, the abundance
of specific miRNAs are highly selective,
and potential indicators and predictors of
human health and disease, including pro-
gressive neurological disorders such as AD
(Alexandrov et al., 2005, 2013; Lukiw and
Pogue, 2007; Pogue et al., 2009; Maciotta
et al., 2013; Zhao et al., 2013).
Lastly, more research into the poten-
tial contribution of aluminum to the AD
process is clearly warranted. There are cur-
rently no treatments for AD that effec-
tively prevent or cure AD’s insidious onset
or propagation. We think it important to
emphasize that the most effective clini-
cal treatment yet devised for moderate- to
late-stage AD patients was the implemen-
tation of the first generation anti-oxidant
and trivalent iron/aluminum chelator des-
ferrioxamine to attempt to remove alu-
minum from the brains of AD patients
(Crapper McLachlan et al., 1991; Percy
et al., 2011). Second generation aluminum
chelators such as Feralex-G, either alone or
in combination with other chelators, has
shown higher specificity, increased selec-
tivity and higher efficacy in aluminum
sequestration and chelation in preliminary
in vitro studies (Kruck et al., 2004, 2008;
Percy et al., 2011; unpublished observa-
tions). Certainly, laboratory experimen-
tation in cultured primary human brain
cells, in transgenic AD animal models, and
clinical studies employing next-generation
aluminum chelators, perhaps in combina-
tion with other drug strategies, are one of
the research areas needing more focused
attention—to more effectively address the
exact role and mechanism of aluminum
neurotoxicity in this rapidly expanding
healthcare concern.
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